The role of hepatic transporters in drug elimination

被引:57
作者
Funk, Christoph [1 ]
机构
[1] F Hoffmann La Roche & Co Ltd, Nonclin Dev, Drug Safety, CH-4070 Basel, Switzerland
关键词
ABC transporter; cholestasis; drug transport; hepatic export; SLC transporter;
D O I
10.1517/17425255.4.4.363
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Hepatic drug transporters of the solute carrier (OATPs, OAT2, OCT1, NTCP) and ABC transporter superfamilies (MDR1, MRPs, BCRP, BSEP) can significantly modulate drug ADME routes. Objective: The currently available literature was reviewed with focus on hepatic drug transporters, related drug-drug interactions and available tools for transporter assessment and extrapolation to in vivo. Conclusions: Hepatic drug transporters have gained additional importance in drug clearance by optimization for basic DMPK properties early on in drug research. However, the lack of selective substrates and inhibitors, proper assessment of the kinetic properties due to interfering passive permeability and multiple binding sites, as well as endogenous transporters present in many cellular assays, are some of the hurdles in studying active drug transport processes. Therefore, data from these in vitro assays have to be carefully evaluated to allow sound extrapolation to the in vivo situation.
引用
收藏
页码:363 / 379
页数:17
相关论文
共 146 条
[1]   Role of transport proteins in drug absorption, distribution and excretion [J].
Ayrton, A ;
Morgan, P .
XENOBIOTICA, 2001, 31 (8-9) :469-497
[2]   Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery [J].
Benet, LZ ;
Izumi, T ;
Zhang, YC ;
Silverman, JA ;
Wacher, VJ .
JOURNAL OF CONTROLLED RELEASE, 1999, 62 (1-2) :25-31
[3]   The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km [J].
Bentz, J ;
Tran, TT ;
Polli, JW ;
Ayrton, A ;
Ellens, H .
PHARMACEUTICAL RESEARCH, 2005, 22 (10) :1667-1677
[4]   Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate [J].
Bode, KA ;
Donner, MG ;
Leier, N ;
Keppler, D .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (01) :151-158
[5]  
BOEHME M, 1994, ADV ENZYME REGUL, V34, P371
[6]   Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats [J].
Bolder, U ;
Trang, NV ;
Hagey, LR ;
Schteingart, CD ;
Ton-Nu, HT ;
Cerrè, C ;
Elferink, RPJO ;
Hofmann, AF .
GASTROENTEROLOGY, 1999, 117 (04) :962-971
[7]   A family of drug transporters: The multidrug resistance-associated proteins [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1295-1302
[8]   Statin safety and drug interactions: Clinical implications [J].
Bottorff, MB .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :27C-31C
[9]   Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells [J].
Briz, O ;
Serrano, MA ;
Rebollo, N ;
Hagenbuch, B ;
Meier, PJ ;
Koepsell, H ;
Marin, JJG .
MOLECULAR PHARMACOLOGY, 2002, 61 (04) :853-860
[10]   The human bile salt export pump: Characterization of substrate specificity and identification of inhibitors [J].
Byrne, JA ;
Strautnieks, SS ;
Mieli-Vergani, G ;
Higgins, CF ;
Linton, KJ ;
Thompson, RJ .
GASTROENTEROLOGY, 2002, 123 (05) :1649-1658